Scan Amidst Prostate Cancer Radioligand Therapy Helps Guide Treatment

by Ramya Rachamanti on  June 25, 2019 at 6:26 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

PSMA positron emission tomography (PET) imaging of patients with metastatic castration-resistant prostate cancer after two cycles of lutetium-177 (177Lu)-PSMA radioligand therapy has shown a significant improvement in patient survival, according to the research presented at the 2019 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
Scan Amidst Prostate Cancer Radioligand Therapy Helps Guide Treatment
Scan Amidst Prostate Cancer Radioligand Therapy Helps Guide Treatment

According to the National Cancer Institute, currently the five-year survival rate for men with metastatic prostate cancer is 30.5 percent. Early assessment of treatment effectiveness is essential to providing optimal care.

Show Full Article


In phase 2 trials, 177Lu-PSMA therapy has shown promising results in treating patients with metastatic castration-resistant prostate cancer. The therapy typically involves a preliminary PSMA PET scan to identify patients who are eligible for the treatment. While interim PET scans have shown high predictive value for lymphoma patients, this concept has not been previously explored in prostate cancer patients undergoing 177Lu-PSMA therapy.

The retrospective analysis was conducted at Klinikum rechts der Isar hospital, Technical University Munich, Germany including patients who underwent gallium-68 (68Ga)-PSMA11 PET/CT at baseline and after two cycles of 177Lu-PSMA RLT under a compassionate use program.

Instead of standardized uptake value, which is the parameter generally used in such analyses, researchers used qPSMA, an in-house developed software, to evaluate the whole-body tumor burden. "Tumor response was assessed by the changes in PSMA-avid tumor volume from baseline to the second PSMA PET using three classification methods," explained Andrei Gafita, MD. "Subsequently, we found that tumor response assessed on interim PSMA PET after two RLT cycles was associated with overall survival."

Gafita stated, "Our results therefore show that interim PSMA PET can be used for therapeutic response assessment in patients undergoing 177Lu-PSMA RLT. Furthermore, occurrence of new lesions in PSMA PET is a prognostic factor for disease progression and could be included in defining tumor response based on PSMA PET imaging."

"While further analyses involving clinical parameters are warranted," Gafita adds, "this analysis paves the way for use of interim PSMA PET in a prospective setting during 177Lu-PSMA radioligand therapy."



Source: Eurekalert

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions
Advertisement

More News on:

Radioisotope Scan Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Reiki and Pranic Healing Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Prostate Cancer: Treatment Options 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive